Karista has led a Series B extension financing round for SamanTree Medical to support the commercial expansion of its Histolog® Scanner technology in the U.S. and Europe.

Target Information

SamanTree Medical, headquartered in Liège, Belgium, is at the forefront of enhancing oncological surgery through innovative imaging technologies. The company is widely recognized for its flagship product, the Histolog® Scanner, which employs advanced massive parallel confocal microscopy. This state-of-the-art technology increases the imaging field up to 40,000 times larger than conventional confocal microscopy, enabling real-time visualization of large, fresh tissue samples with exceptional accuracy. Founded in 2014, SamanTree Medical is built on pioneering research from the École Polytechnique Fédérale de Lausanne (EPFL), a prestigious Swiss institution known for its engineering and technological innovations.

The Histolog® Scanner is CE-marked and FDA-cleared, having already been utilized in over 5,000 surgical procedures focused primarily on prostate and breast cancer. Ongoing studies are exploring its application in additional cancer types, including bladder, penile, lung, and ENT cancers, further validating its potential to revolutionize intraoperative assessments in surgical oncology.

Industry Overview

The market for innovative medical devices in Belgium is on the rise, driven by advancements in technology and a growing emphasis on improving patient outcomes. Belgium is home to a robust healthcare infrastructure, with a strong focus on res